StockNews.com Begins Coverage on Aptevo Therapeutics (NASDAQ:APVO)

StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report report published on Friday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Roth Mkm reduced their price target on shares of Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, September 23rd.

Aptevo Therapeutics Stock Performance

Aptevo Therapeutics stock traded down $0.03 during mid-day trading on Friday, reaching $0.21. 769,567 shares of the company’s stock were exchanged, compared to its average volume of 3,789,151. The business’s fifty day simple moving average is $0.23 and its 200 day simple moving average is $0.45. Aptevo Therapeutics has a one year low of $0.14 and a one year high of $10.80.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned about 18.36% of Aptevo Therapeutics as of its most recent SEC filing. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.